mylan pharma uk limited
mylan pharma uk limited Company Information
Company Number
07838949
Next Accounts
Sep 2025
Shareholders
mcdermott laboratories ltd
Group Structure
View All
Industry
Other research and experimental development on natural sciences and engineering
Registered Address
20 station close, potters bar, hertfordshire, EN6 1TL
Website
www.mylan.co.ukmylan pharma uk limited Estimated Valuation
Pomanda estimates the enterprise value of MYLAN PHARMA UK LIMITED at £105.1m based on a Turnover of £44.1m and 2.38x industry multiple (adjusted for size and gross margin).
mylan pharma uk limited Estimated Valuation
Pomanda estimates the enterprise value of MYLAN PHARMA UK LIMITED at £50.1m based on an EBITDA of £4.4m and a 11.29x industry multiple (adjusted for size and gross margin).
mylan pharma uk limited Estimated Valuation
Pomanda estimates the enterprise value of MYLAN PHARMA UK LIMITED at £80.2m based on Net Assets of £41.7m and 1.93x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Mylan Pharma Uk Limited Overview
Mylan Pharma Uk Limited is a live company located in hertfordshire, EN6 1TL with a Companies House number of 07838949. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in November 2011, it's largest shareholder is mcdermott laboratories ltd with a 100% stake. Mylan Pharma Uk Limited is a established, large sized company, Pomanda has estimated its turnover at £44.1m with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Mylan Pharma Uk Limited Health Check
Pomanda's financial health check has awarded Mylan Pharma Uk Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 1 areas for improvement. Company Health Check FAQs
7 Strong
1 Regular
1 Weak
Size
annual sales of £44.1m, make it larger than the average company (£4.4m)
£44.1m - Mylan Pharma Uk Limited
£4.4m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Mylan Pharma Uk Limited
- - Industry AVG
Production
with a gross margin of 46.8%, this company has a comparable cost of product (46.8%)
46.8% - Mylan Pharma Uk Limited
46.8% - Industry AVG
Profitability
an operating margin of 8.9% make it more profitable than the average company (3.6%)
8.9% - Mylan Pharma Uk Limited
3.6% - Industry AVG
Employees
with 97 employees, this is above the industry average (46)
97 - Mylan Pharma Uk Limited
46 - Industry AVG
Pay Structure
on an average salary of £133.3k, the company has a higher pay structure (£64.6k)
£133.3k - Mylan Pharma Uk Limited
£64.6k - Industry AVG
Efficiency
resulting in sales per employee of £454.2k, this is more efficient (£123.9k)
£454.2k - Mylan Pharma Uk Limited
£123.9k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Mylan Pharma Uk Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 65 days, this is slower than average (44 days)
65 days - Mylan Pharma Uk Limited
44 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Mylan Pharma Uk Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 178 weeks, this is more cash available to meet short term requirements (31 weeks)
178 weeks - Mylan Pharma Uk Limited
31 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 22%, this is a lower level of debt than the average (44.4%)
22% - Mylan Pharma Uk Limited
44.4% - Industry AVG
MYLAN PHARMA UK LIMITED financials
Mylan Pharma Uk Limited's latest turnover from December 2023 is £44.1 million and the company has net assets of £41.7 million. According to their latest financial statements, Mylan Pharma Uk Limited has 97 employees and maintains cash reserves of £39.1 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 44,059,000 | 33,738,000 | 35,184,000 | |||||||||
| Other Income Or Grants | ||||||||||||
| Cost Of Sales | ||||||||||||
| Gross Profit | ||||||||||||
| Admin Expenses | ||||||||||||
| Operating Profit | 3,938,000 | 2,523,000 | 1,852,000 | -15,698,000 | -16,874,000 | -35,566,000 | -70,798,000 | -108,366,000 | -97,551,000 | -66,118,000 | -28,807,000 | -25,168,000 |
| Interest Payable | 1,263,000 | 35,000 | 59,000 | 941,000 | 6,000 | 9,000 | 123,000 | 38,000 | 24,000 | 52,000 | ||
| Interest Receivable | 2,016,000 | 589,000 | 45,000 | 330,000 | 420,000 | 231,000 | 121,000 | 81,000 | 46,000 | 6,000 | 6,000 | 1,000 |
| Pre-Tax Profit | 5,954,000 | 1,849,000 | 1,862,000 | 725,000 | -2,726,000 | 5,538,000 | -960,000 | 11,096,000 | 9,915,000 | 6,870,000 | 3,123,000 | 2,312,000 |
| Tax | -1,454,000 | 127,000 | -248,000 | -219,000 | -148,000 | -875,000 | 42,000 | 282,000 | -844,000 | -1,770,000 | -257,000 | |
| Profit After Tax | 4,500,000 | 1,976,000 | 1,614,000 | 506,000 | -2,874,000 | 4,663,000 | -918,000 | 11,378,000 | 9,071,000 | 5,100,000 | 2,866,000 | 2,312,000 |
| Dividends Paid | ||||||||||||
| Retained Profit | 4,500,000 | 1,976,000 | 1,614,000 | 506,000 | -2,874,000 | 4,663,000 | -918,000 | 11,378,000 | 9,071,000 | 5,100,000 | 2,866,000 | 2,312,000 |
| Employee Costs | 12,930,000 | 11,468,000 | 10,483,000 | 10,402,000 | 10,295,000 | 11,269,000 | 12,637,000 | 12,573,000 | 11,244,000 | 9,169,000 | 7,092,000 | 5,318,000 |
| Number Of Employees | 97 | 90 | 88 | 84 | 90 | 114 | 141 | 142 | 119 | 97 | 75 | 66 |
| EBITDA* | 4,440,000 | 3,006,000 | 2,343,000 | -15,132,000 | -16,225,000 | -34,598,000 | -68,529,000 | -106,955,000 | -96,608,000 | -65,374,000 | -28,178,000 | -24,951,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,839,000 | 1,906,000 | 1,867,000 | 1,846,000 | 2,309,000 | 2,802,000 | 7,147,000 | 8,032,000 | 7,937,000 | 7,782,000 | 4,278,000 | 3,809,000 |
| Intangible Assets | 4,000 | 15,000 | 27,000 | 38,000 | ||||||||
| Investments & Other | ||||||||||||
| Debtors (Due After 1 year) | ||||||||||||
| Total Fixed Assets | 1,839,000 | 1,906,000 | 1,867,000 | 1,846,000 | 2,309,000 | 2,802,000 | 7,147,000 | 8,032,000 | 7,941,000 | 7,797,000 | 4,305,000 | 3,847,000 |
| Stock & work in progress | ||||||||||||
| Trade Debtors | 71,000 | |||||||||||
| Group Debtors | 11,116,000 | 12,817,000 | 12,013,000 | 16,936,000 | 29,598,000 | 27,854,000 | 17,814,000 | |||||
| Misc Debtors | 1,328,000 | 2,139,000 | 1,769,000 | 2,182,000 | 2,186,000 | 4,048,000 | 6,562,000 | 6,600,000 | 11,406,000 | 13,111,000 | 1,760,000 | 1,817,000 |
| Cash | 39,108,000 | 42,398,000 | 33,155,000 | 15,688,000 | 3,438,000 | 6,997,000 | 12,974,000 | 20,900,000 | 35,085,000 | 1,177,000 | 4,636,000 | 1,624,000 |
| misc current assets | 3,000 | |||||||||||
| total current assets | 51,552,000 | 57,354,000 | 46,937,000 | 34,877,000 | 35,222,000 | 38,899,000 | 37,350,000 | 27,503,000 | 46,491,000 | 14,288,000 | 6,396,000 | 3,441,000 |
| total assets | 53,391,000 | 59,260,000 | 48,804,000 | 36,723,000 | 37,531,000 | 41,701,000 | 44,497,000 | 35,535,000 | 54,432,000 | 22,085,000 | 10,701,000 | 7,288,000 |
| Bank overdraft | ||||||||||||
| Bank loan | ||||||||||||
| Trade Creditors | 4,214,000 | 3,915,000 | 14,458,000 | 1,238,000 | 1,678,000 | 1,575,000 | 1,631,000 | |||||
| Group/Directors Accounts | 1,063,000 | 13,881,000 | 248,000 | 1,163,000 | 11,082,000 | |||||||
| other short term finances | ||||||||||||
| hp & lease commitments | ||||||||||||
| other current liabilities | 6,090,000 | 4,842,000 | 2,659,000 | 3,752,000 | 5,652,000 | 11,892,000 | 4,806,000 | 23,999,000 | 11,805,000 | 5,521,000 | 4,975,000 | |
| total current liabilities | 11,367,000 | 22,638,000 | 14,458,000 | 4,145,000 | 5,430,000 | 7,227,000 | 14,686,000 | 4,806,000 | 35,081,000 | 11,805,000 | 5,521,000 | 4,975,000 |
| loans | ||||||||||||
| hp & lease commitments | ||||||||||||
| Accruals and Deferred Income | ||||||||||||
| other liabilities | ||||||||||||
| provisions | 363,000 | 321,000 | 626,000 | 472,000 | 501,000 | |||||||
| total long term liabilities | 363,000 | 321,000 | 626,000 | 472,000 | 501,000 | |||||||
| total liabilities | 11,730,000 | 22,959,000 | 15,084,000 | 4,617,000 | 5,931,000 | 7,227,000 | 14,686,000 | 4,806,000 | 35,081,000 | 11,805,000 | 5,521,000 | 4,975,000 |
| net assets | 41,661,000 | 36,301,000 | 33,720,000 | 32,106,000 | 31,600,000 | 34,474,000 | 29,811,000 | 30,729,000 | 19,351,000 | 10,280,000 | 5,180,000 | 2,313,000 |
| total shareholders funds | 41,661,000 | 36,301,000 | 33,720,000 | 32,106,000 | 31,600,000 | 34,474,000 | 29,811,000 | 30,729,000 | 19,351,000 | 10,280,000 | 5,180,000 | 2,313,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Operating Profit | 3,938,000 | 2,523,000 | 1,852,000 | -15,698,000 | -16,874,000 | -35,566,000 | -70,798,000 | -108,366,000 | -97,551,000 | -66,118,000 | -28,807,000 | -25,168,000 |
| Depreciation | 502,000 | 483,000 | 491,000 | 566,000 | 649,000 | 968,000 | 2,269,000 | 1,407,000 | 932,000 | 732,000 | 618,000 | 209,000 |
| Amortisation | 4,000 | 11,000 | 12,000 | 11,000 | 8,000 | |||||||
| Tax | -1,454,000 | 127,000 | -248,000 | -219,000 | -148,000 | -875,000 | 42,000 | 282,000 | -844,000 | -1,770,000 | -257,000 | |
| Stock | ||||||||||||
| Debtors | -2,512,000 | 1,174,000 | -5,407,000 | -12,595,000 | -118,000 | 7,526,000 | 17,776,000 | -4,806,000 | -1,705,000 | 11,351,000 | -57,000 | 1,817,000 |
| Creditors | 299,000 | -10,543,000 | 13,220,000 | -440,000 | 103,000 | -56,000 | 1,631,000 | |||||
| Accruals and Deferred Income | 1,248,000 | 4,842,000 | -2,659,000 | -1,093,000 | -1,900,000 | -6,240,000 | 7,086,000 | -19,193,000 | 12,194,000 | 6,284,000 | 546,000 | 4,975,000 |
| Deferred Taxes & Provisions | 42,000 | -305,000 | 154,000 | -29,000 | 501,000 | |||||||
| Cash flow from operations | 7,087,000 | -4,047,000 | 18,217,000 | -4,318,000 | -17,551,000 | -49,295,000 | -77,546,000 | -121,060,000 | -83,553,000 | -72,211,000 | -27,832,000 | -21,793,000 |
| Investing Activities | ||||||||||||
| capital expenditure | ||||||||||||
| Change in Investments | ||||||||||||
| cash flow from investments | ||||||||||||
| Financing Activities | ||||||||||||
| Bank loans | ||||||||||||
| Group/Directors Accounts | -12,818,000 | 13,881,000 | -248,000 | 248,000 | -1,163,000 | 1,163,000 | -11,082,000 | 11,082,000 | ||||
| Other Short Term Loans | ||||||||||||
| Long term loans | ||||||||||||
| Hire Purchase and Lease Commitments | ||||||||||||
| other long term liabilities | ||||||||||||
| share issue | ||||||||||||
| interest | 2,016,000 | -674,000 | 10,000 | 271,000 | -521,000 | 225,000 | 112,000 | -42,000 | 8,000 | -18,000 | 6,000 | -51,000 |
| cash flow from financing | -9,942,000 | 13,812,000 | -238,000 | 519,000 | -521,000 | -938,000 | 1,275,000 | -11,124,000 | 11,090,000 | -18,000 | 7,000 | -50,000 |
| cash and cash equivalents | ||||||||||||
| cash | -3,290,000 | 9,243,000 | 17,467,000 | 12,250,000 | -3,559,000 | -5,977,000 | -7,926,000 | -14,185,000 | 33,908,000 | -3,459,000 | 3,012,000 | 1,624,000 |
| overdraft | ||||||||||||
| change in cash | -3,290,000 | 9,243,000 | 17,467,000 | 12,250,000 | -3,559,000 | -5,977,000 | -7,926,000 | -14,185,000 | 33,908,000 | -3,459,000 | 3,012,000 | 1,624,000 |
mylan pharma uk limited Credit Report and Business Information
Mylan Pharma Uk Limited Competitor Analysis
Perform a competitor analysis for mylan pharma uk limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other large companies, companies in EN6 area or any other competitors across 12 key performance metrics.
mylan pharma uk limited Ownership
MYLAN PHARMA UK LIMITED group structure
Mylan Pharma Uk Limited has no subsidiary companies.
Ultimate parent company
MYLAN NV
#0066723
MCDERMOTT LABORATORIES LIMITED
IE110075
2 parents
MYLAN PHARMA UK LIMITED
07838949
mylan pharma uk limited directors
Mylan Pharma Uk Limited currently has 3 directors. The longest serving directors include Ms Caroline Dixon (Apr 2012) and Dr Walter Cook (Jun 2017).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Ms Caroline Dixon | England | 56 years | Apr 2012 | - | Director |
| Dr Walter Cook | England | 57 years | Jun 2017 | - | Director |
| Mr Rupert Cory | United Kingdom | 52 years | Mar 2020 | - | Director |
P&L
December 2023turnover
44.1m
+31%
operating profit
3.9m
+56%
gross margin
46.8%
-0.72%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
41.7m
+0.15%
total assets
53.4m
-0.1%
cash
39.1m
-0.08%
net assets
Total assets minus all liabilities
mylan pharma uk limited company details
company number
07838949
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
November 2011
age
14
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
DELOITTE LLP
address
20 station close, potters bar, hertfordshire, EN6 1TL
Bank
-
Legal Advisor
-
mylan pharma uk limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to mylan pharma uk limited.
mylan pharma uk limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for MYLAN PHARMA UK LIMITED. This can take several minutes, an email will notify you when this has completed.
mylan pharma uk limited Companies House Filings - See Documents
| date | description | view/download |
|---|
